Recent 8-K filings for JAGX
Highest-materiality recent filing
Jaguar Health receives Nasdaq delisting notice for insufficient publicly held shares after reverse split
- Post 1-for-35 reverse stock split on April 30, 2026, publicly held shares are ~401,226, below 500,000 minimum.
- Nasdaq Staff notified company on May 1, 2026 of additional deficiency under Listing Rule 5550(a)(4).
-
Jaguar Health issues 64,668 common shares for Series Q Preferred; annual meeting adjourned to June 8
Issued 31,958 and 32,710 common shares to Streeterville on May 26 and June 1, 2026, respectively, in exchange for 3.72 and 4.2 Series Q Preferred shares.
-
Jaguar Health regains Nasdaq Bid Price compliance; monitoring until May 2027
Formal notice from Nasdaq on May 26, 2026: Jaguar complies with Bid Price Rule (closing bid ≥$1/sh).
-
Issued 54,222 common shares to Streeterville in exchange for 7.96 shares of Series Q Preferred Stock.
-
Jaguar Health Q1 revenue up 816% to $20.3M on $19M license deal; net loss narrows to $7.0M
Total revenue $20.3M (816% YoY increase) driven by $19.1M license revenue from Woodward/Future Pak deal.
-
Jaguar Health exchanges $22.7M in royalty interests for Series Q Preferred Stock
Uptown Capital: $12.5M royalty reduction for 500 Series Q shares.
-
Jaguar Health gets Nasdaq extension to May 18 for bid-price compliance; delisting risk remains
Received Nasdaq Staff notice on May 1, 2026 for non-compliance with 500,000 publicly held shares requirement.
-
Post 1-for-35 reverse stock split on April 30, 2026, publicly held shares are ~401,226, below 500,000 minimum.
-
Jaguar Health cures Nasdaq publicly held shares deficiency via warrant exercises after reverse split
Received Nasdaq notice on May 1, 2026 for non-compliance with minimum 500,000 publicly held shares after 1-for-35 reverse split on April 30.
-
Jaguar Health granted Nasdaq extension to May 15, 2026; announces 1-for-35 reverse stock split
Nasdaq Panel grants extension until May 15, 2026 to demonstrate compliance with $1.00 minimum bid price rule.
-
Jaguar Health stockholders approve authorized share increase and two reverse stock split proposals
Authorized common stock increased from 298M to 500M shares; total authorized shares from 352M to 554M.
-
Jaguar Health regains Nasdaq equity compliance after $27M in capital events
Stockholders' deficit was $18.7M at Dec 31, 2025, below Nasdaq's $2.5M minimum.
-
Net revenue FY2025 $11.5M (-1.5% YoY); Q4 2025 net revenue $3.2M (+5% QoQ, -8% YoY).
-
Jaguar Health postpones royalty payments, extends notes, terminates 48,211 warrants
Royalty payment start postponed to July 1, 2026; Uptown amount reduced to $11,125,282.54, Streeterville to $12,428,782.20.
-
Jaguar Health receives Nasdaq delisting notice for bid price; plans to appeal
Nasdaq notice on March 5, 2026: bid price below $1.00 for 30 consecutive business days.
-
Jaguar Health files Series O Preferred Stock certificate for special dividend payable March 4
Filed Certificate of Designation for 1,557,000 shares of Series O Convertible Preferred Stock.
-
Jaguar Health declared a one-time special stock dividend of Series O Preferred Stock on February 18, 2026.
-
Jaguar Health issues ~11.8M pre-funded warrants to reduce $2.04M in royalties and preferred stock
Reduced $1.19M Iliad royalty and $0.85M Streeterville royalty by issuing 1.55M and 1.11M pre-funded warrants.
-
Exclusive license to Future Pak for Mytesi (HIV/AIDS diarrhea) and Canalevia-CA1 (chemotherapy-induced diarrhea in dogs) in U.S.
-
Jaguar Health issues $350K in 6% notes with warrants; corrects prior filing dates
Issued $350,000 aggregate principal amount of 6% unsecured promissory notes to two accredited investors.
-
Jaguar Health issues $350K in 6% notes and warrants for 350K shares at $1.00
Issued $350,000 aggregate principal amount of unsecured promissory notes to two accredited investors.
-
Jaguar Health closes $350K private placement of 6% notes and warrants for working capital
Issued $350K aggregate principal of 6% unsecured promissory notes to accredited investors on Jan 6, 2026.
-
Jaguar Health swaps 91 Series M Preferred shares for 440K common shares and 1.6M pre-funded warrants
On Dec 9, exchanged 75 Series M Preferred for 400K common shares and warrant for 1,304,545 shares at $0.001.
-
JAGX stockholders approve three proposals; crofelemer MVID trial shows up to 37% PS reduction
Stockholders approved proposal to issue shares upon exchange/redemption of Series N Preferred Stock (1,032,716 For, 73,065 Against).
-
Jaguar Health amends $36M royalty obligations, extends debt, exchanges preferred for common
Royalty Interest amendments set minimum monthly payment of $750,000 per $12M royalty from April 1, 2026.
-
Jaguar Health issues $10.81M secured note to Streeterville Capital; $8M held as collateral
Net proceeds of $10M after $800K OID and $10K transaction expenses; interest 8% p.a., maturity 36 months.
-
Jaguar Health issues 286,532 shares to reduce royalty interest by $600,000
Issued 286,532 common shares in exchange for $600,000 reduction in outstanding royalty interest balance.
-
Jaguar Health raises $1M via PIPE: 161,583 shares + 479,442 pre-funded warrants at $1.56/share
Issued 161,583 common shares and 479,442 pre-funded warrants to Brown Stone Capital at $1.56/share (warrant price $1.5599); total proceeds $1M.
-
Jaguar Health raises $2.38M via Series N Perpetual Preferred Stock PIPE
Issued ~951 Series N Preferred shares at $2,500 stated value each for aggregate proceeds of $2.38M.
-
Jaguar Health: Crofelemer cuts TPN needs in MVID/SBS; FDA outlines sNDA path for breast cancer
All 7 proposals approved at Aug 19 annual meeting; directors elected, stock plan amended, share issuances authorized.
-
Jaguar Health extends ATM manager Lucid's term to Dec 31, 2025
Sixth ATM Amendment extends Lucid Capital Markets' service as manager from June 30 to Dec 31, 2025.
-
Jaguar Health cuts royalty debt by $6.5M, issues Series M preferred to Iliad and Streeterville
Issued 170 shares of Series M Preferred to Iliad for $4.25M reduction in October 2020 royalty interest.
-
Company entered Exchange Agreements with certain investors to replace ~$2.57M of 6% convertible notes originally due June 30, 2025; new maturity January 30, 2026.
-
Jaguar Health raises ~$1.5M in registered direct offering with warrants
Issued 246,306 shares at $6.09/share; gross proceeds ~$1.5M.
-
Jaguar Health reduces royalty debt by $1.016M via equity exchanges; Q1 results released
Issued 60,000 shares to Iliad for $466,200 reduction in October 2020 royalty interest.
-
Jaguar Health posts investor presentation on website; no specific content disclosed in filing
Slide presentation made available on May 9, 2025 under Item 7.01.
-
Jaguar Health obtains waiver from noteholders to resume ATM stock sales
Investors holding majority of $3.4M convertible notes waived VRT restriction.
-
Jaguar Health issues 57,500 shares to reduce royalty interest by $632,500
On April 30, 2025, issued 57,500 shares to a royalty interest holder in exchange for $632,500 reduction in outstanding balance.
-
Crofelemer reduces TPN up to 27% in MVID and 12.5% in SBS-IF in proof-of-concept trial
Initial POC data shows novel liquid crofelemer reduced parenteral support in MVID and SBS-IF patients by up to 27% and 12.5% respectively.
-
Jaguar Health to discuss initial crofelemer POC results for MVID and SBS-IF on April 30 webcast
Data presented April 26 at ELITE PED-GI Congress by Dr. Mohamad Miqdady.
-
Jaguar Health extends note maturity to July 2025, reduces royalty balance by $1.09M via stock
Issued 1,290,000 shares to a royalty holder in exchange for $1,094,952 reduction in outstanding royalty balance.
-
Jaguar Health files updated investor presentation for Ped-GI congress; no detailed data
CEO references updated investor presentation at 11th Annual Elite Ped-GI Congress 2025 in Abu Dhabi.
-
Jaguar Health to present at Elite Ped-GI Congress 2025; updated investor deck furnished
Presentation scheduled April 24-26, 2025 in Abu Dhabi, UAR.
-
Jaguar Health closes $3.45M convertible note private placement with warrants
Issued $3.448M aggregate principal of convertible notes; 6% interest, 3-month maturity, immediately convertible.
-
Jaguar Health 2024 revenue $11.7M, up 20% YoY; net loss narrows to $38.5M
2024 net revenue of ~$11.7M (prescription+non-prescription+license) increased ~20% from $9.8M in 2023.
-
Jaguar Health raises $3.45M via convertible notes; CEO & insiders participate
$3.448M aggregate principal convertible notes at 6% interest, 3-month maturity, convertible into common stock at ~$5.54/share.
-
Jaguar Health announces 1-for-25 reverse stock split effective March 24 to meet Nasdaq compliance
Reverse split at 1-for-25 ratio, effective March 24, 2025 at 12:01 am ET.
-
Shareholders voted 5,281,329 for and 1,377,494 against the reverse stock split (ratio 1:15 to 1:40); board to set exact ratio by March 2026.
-
Jaguar Health adopts 1-year rights plan after receiving acquisition interest
Board adopted limited-duration rights plan on Feb 26, 2025; expires Feb 26, 2026.
-
Jaguar Health extends maturity of $6.22M secured note to Jan 20, 2026
Note originally issued Jan 19, 2021; maturity extended from undated to Jan 20, 2026.
-
Jaguar Health extends note maturity to July 2025, issues shares to reduce royalty liability
Note amendment with Streeterville Capital extends maturity of $6.22M secured promissory note to July 20, 2025.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.85 · Median 0.60 · Most common event other_material